Evidence map›Paper›PMID 28278515›Full record

Trial reportBritish journal of cancer2017

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.

Hui-Ming Lin, Kate L Mahon, Calan Spielman, Howard Gurney, Girish Mallesara, Martin R Stockler, Patricia Bastick, Karen Briscoe, Gavin Marx, Alexander Swarbrick and 1 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Follow-Up Biomarkers in the Evolution of Prostate Cancer, Levels ofInternational journal of molecular sciences · 2022
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Hui-Ming LinCancer Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia.
Kate L MahonCancer Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia.
Calan SpielmanCancer Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia.
Howard GurneyCrown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales 2145, Australia.
Girish MallesaraPharmacogenomics Research for Individualised Medicine (PRIMe) consortium, New South Wales, Australia.
Martin R StocklerDepartment of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales 2050, Australia.
Patricia BastickPharmacogenomics Research for Individualised Medicine (PRIMe) consortium, New South Wales, Australia.
Karen BriscoePharmacogenomics Research for Individualised Medicine (PRIMe) consortium, New South Wales, Australia.
Gavin MarxPharmacogenomics Research for Individualised Medicine (PRIMe) consortium, New South Wales, Australia.
Alexander SwarbrickCancer Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia.
Lisa G HorvathCancer Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia.
The Kinghorn Cancer Centre · AUGarvan Institute of Medical Research · AUChris O’Brien Lifehouse · AUSt George Hospital · AUSydney Adventist Hospital · AUWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiomarkers of therapeutic response and prognosis are needed to assist in the sequencing of treatments for metastatic castration-resistant prostate cancer (CRPC). Previously in a Phase 1 discovery study, we identified 14 circulating microRNAs that were associated with response to docetaxel chemotherapy or overall survival. We performed a Phase 2 validation study to verify these findings.

methodsUsing real-time PCR, the levels of the 14 microRNAs were measured in plasma collected before and after the first cycle of docetaxel from a Phase 2 cohort of 89 patients.

resultsThe microRNAs were not associated with docetaxel response in the Phase 2 cohort. Higher baseline levels of six microRNAs, predominantly of the miR-200 family, were confirmed to be associated with shorter overall survival. A microRNA signature comprising these six microRNAs predicted high-risk patients in the Phase 2 cohort with a hazard ratio of 4.12 (95% CI 2.20-7.70, P=0.000001). The signature was an independent predictor in multivariable analysis with clinicopathological factors.

conclusionsThe association of circulating microRNAs with overall survival suggests their involvement in CRPC progression.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorClinical Trials, Phase I as TopicCohort StudiesDisease ProgressionDocetaxelFollow-Up StudiesHumansMaleMicroRNAsMiddle AgedNeoplasm GradingNeoplasm StagingAntineoplastic AgentsBiomarkers, TumorDocetaxelMicroRNAsTaxoids

Identifiers

PMID28278515
PMCPMC5396108
OpenAlexW2592027438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.